193 related articles for article (PubMed ID: 36333070)
101. Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: A Meta-Analysis.
Wan Z; Han B
Front Oncol; 2020; 10():579221. PubMed ID: 33117717
[TBL] [Abstract][Full Text] [Related]
102. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
Lussana F; Rambaldi A; Finazzi MC; van Biezen A; Scholten M; Oldani E; Carobbio A; Iacobelli S; Finke J; Nagler A; Volin L; Lamy T; Arnold R; Mohty M; Michallet M; de Witte T; Olavarria E; Kröger N
Haematologica; 2014 May; 99(5):916-21. PubMed ID: 24389309
[TBL] [Abstract][Full Text] [Related]
103. Myeloproliferative and lymphoproliferative disorders: State of the art.
Rumi E; Baratè C; Benevolo G; Maffioli M; Ricco A; Sant'Antonio E
Hematol Oncol; 2020 Apr; 38(2):121-128. PubMed ID: 31833567
[TBL] [Abstract][Full Text] [Related]
104. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
105. Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN.
Davidson MB; Kennedy JA; Capo-Chichi JM; Shi Y; Xu W; Cheung V; Arruda A; Bankar A; Richard-Carpentier G; Chan S; Maze D; Minden MD; Schimmer AD; Schuh AC; Sibai H; Yee K; Tierens A; Viswabandya A; Gupta V
Blood Adv; 2024 Mar; 8(5):1281-1294. PubMed ID: 38170760
[TBL] [Abstract][Full Text] [Related]
106. [Clinical impact of gene mutations on myeloproliferative neoplasms in Japan].
Morishita S
Rinsho Ketsueki; 2021; 62(8):1060-1069. PubMed ID: 34497192
[TBL] [Abstract][Full Text] [Related]
107. Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians.
Kaifie A; Isfort S; Gattermann N; Hollburg W; Klausmann M; Wolf D; Maintz C; Hänel M; Goekkurt E; Göthert JR; Platzbecker U; Geer T; Parmentier S; Jost E; Serve H; Ehninger G; Berdel WE; Brümmendorf TH; Koschmieder S;
Ann Hematol; 2016 Sep; 95(9):1399-410. PubMed ID: 27334946
[TBL] [Abstract][Full Text] [Related]
108. Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases.
Noor SJ; Tan W; Wilding GE; Ford LA; Barcos M; Sait SN; Block AW; Thompson JE; Wang ES; Wetzler M
Leuk Res; 2011 May; 35(5):608-13. PubMed ID: 20727590
[TBL] [Abstract][Full Text] [Related]
109. Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features.
Ouyang J; Zheng W; Shen Q; Goswami M; Jorgensen JL; Medeiros LJ; Wang SA
Cytometry B Clin Cytom; 2014 Dec; ():. PubMed ID: 25504846
[TBL] [Abstract][Full Text] [Related]
110. Molecular Progression of Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms: A Study on Sequential Bone Marrow Biopsies.
Brune MM; Rau A; Overkamp M; Flaadt T; Bonzheim I; Schürch CM; Federmann B; Dirnhofer S; Fend F; Tzankov A
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830756
[TBL] [Abstract][Full Text] [Related]
111. Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia.
de Castro FA; Mehdipour P; Chakravarthy A; Ettayebi I; Loo Yau H; Medina TS; Marhon SA; de Almeida FC; Bianco TM; Arruda AGF; Devlin R; de Figueiredo-Pontes LL; Chahud F; da Costa Cacemiro M; Minden MD; Gupta V; De Carvalho DD
Br J Haematol; 2024 Jan; 204(1):206-220. PubMed ID: 37726227
[TBL] [Abstract][Full Text] [Related]
112. Proof of concept of triple COMBI therapy to prohibit MPN progression to AML.
Hasselbalch HC; Skov V; Kjaer L; Larsen MK
Br J Haematol; 2024 Jan; 204(1):16-18. PubMed ID: 37957927
[TBL] [Abstract][Full Text] [Related]
113. Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor Therapy.
Handa S; Sivakumar G; Srisuwananukorn A; Dueck A; Tremblay D; Mascarenhas JO; Ginzburg Y; Kremyanskaya M; Hoffman R
Clin Lymphoma Myeloma Leuk; 2024 May; ():. PubMed ID: 38839448
[TBL] [Abstract][Full Text] [Related]
114. LKB1/
Marinaccio C; Suraneni P; Celik H; Volk A; Wen QJ; Ling T; Bulic M; Lasho T; Koche RP; Famulare CA; Farnoud N; Stein B; Schieber M; Gurbuxani S; Root DE; Younger ST; Hoffman R; Gangat N; Ntziachristos P; Chandel NS; Levine RL; Rampal RK; Challen GA; Tefferi A; Crispino JD
Cancer Discov; 2021 Jun; 11(6):1398-1410. PubMed ID: 33579786
[TBL] [Abstract][Full Text] [Related]
115. Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms.
Calabresi L; Carretta C; Romagnoli S; Rotunno G; Parenti S; Bertesi M; Bartalucci N; Rontauroli S; Chiereghin C; Castellano S; Gentili G; Maccari C; Vanderwert F; Mannelli F; Della Porta M; Manfredini R; Vannucchi AM; Guglielmelli P
Am J Hematol; 2023 Oct; 98(10):1520-1531. PubMed ID: 37399248
[TBL] [Abstract][Full Text] [Related]
116. Blast Phase of Myeloproliferative Neoplasm Resembles Acute Myeloid Leukemia, Myelodysplasia-Related, in Clinical Presentation, Cytogenetic Pattern, and Genomic Profile, and Often Undergoes Reversion to Second Chronic Phase Status After Induction Chemotherapy.
Zhao Y; Siddiqi I; Wildes TJ; Charles D; Deak K; Wang E
Arch Pathol Lab Med; 2024 Mar; ():. PubMed ID: 38426696
[TBL] [Abstract][Full Text] [Related]
117. Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival.
Abdelmagid MG; Al-Kali A; Begna KH; Hogan WJ; Litzow MR; Fleti F; Mangaonkar AA; Patnaik MS; Elliott MA; Alkhateeb H; Shi M; Howard MT; Reichard KK; Ketterling RP; Shah M; Pardanani A; Gangat N; Tefferi A
Haematologica; 2023 Sep; 108(9):2542-2545. PubMed ID: 36794509
[No Abstract] [Full Text] [Related]
118. CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases.
Ilyas R; McCullough K; Badar T; Patnaik MM; Alkhateeb H; Mangaonkar A; Pardanani A; Tefferi A; Gangat N
Blood Cancer J; 2023 Feb; 13(1):26. PubMed ID: 36797234
[No Abstract] [Full Text] [Related]
119. Acute Myeloid Leukemia Following Myeloproliferative Neoplasms: A Review of What We Know, What We Do Not Know, and Emerging Treatment Strategies.
McKinnell Z; Karel D; Tuerff D; Sh Abrahim M; Nassereddine S
J Hematol; 2022 Dec; 11(6):197-209. PubMed ID: 36632576
[TBL] [Abstract][Full Text] [Related]
120. [Clinical Value of Genetic Susceptibility Genes for Myeloid Neoplasm in Myeloproliferative Neoplasm].
Gao S; Duan YF; Zhang YH; Teng GS; DU CX; Bai J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Auguest; 31(4):1119-1124. PubMed ID: 37551486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]